Aardvark Therapeutics, Inc. (AARD) stock

AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30

$1.33−0.19 (-12.50%)

Close on Nov 13, 2026Market cap $29.11MP/E –Yield –

Aardvark Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Aardvark Therapeutics's enterprise value was -$39.10M on Nov 11, 2026, against $90.62M a year earlier.

Period	Period end	Value	Change
2026	Nov 11, 2026	-$39.10M	-124.6%
2025	Dec 31, 2025	$159.01M	–

Parsed from the XBRL in Aardvark Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AARD.

Advertisement
300 × 250

See a number that looks wrong?